Why Is Moderna (MRNA) Stock Price Down 5.77% Today, Aug 26? Post-Rally Valuation Reassessment Triggers Pullback

Moderna shares fell 5.77% as investors reassessed valuation after a vaccine-data-driven rally, with no new same-session filings or clinical updates cited. The pullback appears driven by profit-taking and uncertainty around the magnitude and commercialization path of the Merck-partnered cancer-vaccine opportunity. A slightly risk-off macro tape following hotter inflation data likely reinforced sensitivity to valuation, but looks secondary to company-specific repricing dynamics.